Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Quest Diagnostics achieved a real regulatory win, but financial impact remains completely unquantified.

What the company is saying

Quest Diagnostics is positioning the New York State Department of Health’s approval of its Haystack MRD test as a major regulatory milestone, emphasizing that this now enables the test’s use in all 50 U.S. states. The company’s narrative centers on the test’s clinical utility, referencing a 'landmark' study published in The New England Journal of Medicine and highlighting the test’s ability to identify clinical complete response at a median of 1.4 months versus over 6 months for imaging. Management frames the approval as validation of both the test’s scientific rigor and the company’s longstanding expertise, referencing over 20 years of collaboration in liquid biopsy technologies. The announcement repeatedly stresses the breadth of Quest’s operational reach—serving half of U.S. physicians and hospitals, one in three American adults annually, and employing nearly 57,000 people. The language is confident and measured, with only mild promotional flourishes (e.g., 'culmination of over 20 years of collaboration,' 'rigorous investigational settings'). Notably, the company foregrounds regulatory and clinical achievements while omitting any discussion of commercial adoption, revenue, pricing, or competitive positioning. The only forward-looking statements are generic, such as 'we look forward to extending access' and a call for continued study as the test is integrated into practice. Two notable individuals are named: Dan Edelstein (VP and GM for Haystack Oncology) and Dr. Andrea Cercek (lead investigator of the cited study), but neither is presented as an external investor or strategic partner; their involvement signals operational and clinical credibility, not new capital or distribution leverage. This narrative fits Quest’s broader investor relations strategy of emphasizing scientific and regulatory leadership, but it is notably silent on financial outcomes or market share ambitions. Compared to typical biotech announcements, the messaging is restrained, with no shift toward hype or speculative projections.

What the data suggests

The disclosed data is almost entirely non-financial, focusing on regulatory status, clinical validation, and operational footprint. The key quantitative highlight is that Haystack MRD identified clinical complete response at a median of 1.4 months, compared to more than 6 months for imaging, as published in May 2025 in The New England Journal of Medicine. The test has been available for clinician ordering since late 2024 in 49 states and D.C., and is now authorized in all 50 states following New York’s approval. The FDA granted Breakthrough Device Designation in 2025 for Stage II colorectal cancer, which is a meaningful regulatory milestone but not a commercial one. Quest’s operational scale is underscored by serving half of U.S. physicians and hospitals, one in three American adults annually, and employing nearly 57,000 people. However, there are no financial figures—no revenue, cost, margin, or adoption rates—nor any period-over-period comparisons. The gap between the company’s claims and the numbers is that while regulatory and clinical milestones are well-supported, there is zero evidence provided for commercial traction or financial impact. Prior targets or guidance are not referenced, so it is impossible to assess whether expectations have been met or missed. The quality of the regulatory and clinical disclosures is high, but the absence of financial data is a glaring omission for investors. An independent analyst would conclude that the regulatory achievement is real and significant, but that the financial implications are entirely opaque.

Analysis

The announcement is focused on a realised regulatory milestone: the approval of the Haystack MRD test by the New York State Department of Health, which now enables its use in all 50 U.S. states. The claims are factual, supported by regulatory and clinical evidence, including a published study with specific numerical outcomes (median time to clinical complete response). There are no forward-looking financial projections, aspirational language about future revenues, or unsubstantiated claims about market impact. The only forward-looking statements are generic and do not form the core of the announcement. No large capital outlay or delayed benefit is disclosed. The tone is positive but proportionate to the achievement, with no exaggeration relative to the evidence.

Risk flags

• ●Lack of financial disclosure: The announcement provides no revenue, pricing, margin, or adoption data for Haystack MRD. This matters because investors cannot assess the commercial impact or profitability of the test, making it impossible to model financial upside or downside.
• ●No commercial adoption metrics: While regulatory approval is achieved, there is no evidence of clinician uptake, payer reimbursement, or patient volume. Without these, the test’s financial contribution could be negligible despite broad authorization.
• ●Omission of competitive landscape: The company does not mention competitors, alternative technologies, or market share, leaving investors blind to potential threats or the true addressable market.
• ●Forward-looking integration risk: The only forward-looking statements pertain to integrating the test into clinical practice, which is a non-trivial hurdle. Even with regulatory approval, actual adoption by clinicians and payers can lag or fail to materialize.
• ●Geographic and operational complexity: The test is available for clinical trials in the United States, Germany, and Finland, but the announcement does not clarify regulatory or commercial status outside the U.S. This could create confusion about the global opportunity or regulatory hurdles.
• ●Absence of financial guidance or targets: There is no mention of expected revenue, market penetration, or profitability timelines, which is unusual for a major product launch and increases uncertainty for investors.
• ●Potential for overstatement of impact: The announcement uses strong language about clinical utility and operational reach, but without financial or adoption data, there is a risk that the real-world impact is overstated relative to the achievement.
• ●Reliance on single study for clinical claims: The clinical utility claim is based on a single published study. If subsequent research fails to replicate these results, the perceived value of the test could diminish.

Bottom line

For investors, this announcement means that Quest Diagnostics has achieved a genuine regulatory milestone: Haystack MRD is now approved for use in all 50 U.S. states, with supporting evidence from a published clinical study and FDA Breakthrough Device Designation. However, the company provides no information on how this will translate into revenue, profit, or market share—there are no adoption rates, pricing details, or financial projections. The narrative is credible as far as regulatory and clinical facts go, but the lack of commercial data is a major limitation for investment analysis. No notable institutional investors or external strategic partners are involved in this announcement, so there is no additional signal of market validation or capital support. To change this assessment, Quest would need to disclose test volumes, revenue impact, payer coverage, or binding commercial agreements in future updates. Investors should watch for these metrics in the next reporting period, as well as any evidence of competitive response or changes in reimbursement policy. At this stage, the information is worth monitoring but not acting on, as the regulatory win is real but the financial upside is unproven. The single most important takeaway is that while Quest has cleared a key regulatory hurdle, the commercial and financial implications remain entirely to be demonstrated.

Announcement summary

(NYSE: DGX) Quest Diagnostics announced that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers. With this approval, Haystack MRD is now authorized for patient testing in all 50 U.S. states. The test has been available for clinician ordering since late 2024 in 49 states and the District of Columbia. Haystack MRD's clinical utility was demonstrated in a landmark study led by Dr. Andrea Cercek at Memorial Sloan Kettering Cancer Center and published in The New England Journal of Medicine in May 2025, where ctDNA testing identified clinical complete response at a median of 1.4 months, compared to more than 6 months using imaging methods. The FDA granted Haystack MRD Breakthrough Device Designation in 2025 for use in Stage II colorectal cancer. Haystack MRD is also available for clinical trials as an investigational device in laboratories located in Baltimore, Maryland; Hamburg, Germany; and Helsinki, Finland. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, with nearly 57,000 employees.

Disagree with this article?